Dynamine (Methylliberine) – Kodiac biolabs

Plain-language summaryIntrigue 38 / 100

Dynamine (methylliberine) is a purine alkaloid related to theacrine, marketed in pre-workout formulations as a longer-lasting alternative to caffeine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundOverhyped vs evidence

22/100

Proprietary purine alkaloid with derivative caffeine-like mechanism and manufacturer-funded evidence base

Look, Dynamine is a supplement industry compound first and a research target second. Methylliberine is a purine alkaloid isolated from kucha tea, a close structural relative of theacrine and, further up the family tree, caffeine. The proposed mechanism is adenosine receptor antagonism, which puts it squarely in one of the most thoroughly worked territories in pharmacology. When your mechanism is “probably like caffeine but maybe a bit faster,” you’re not giving a bench scientist much to get excited about.

The compound’s commercial origin shapes everything about the evidence base. Compound Solutions holds the trademark on Dynamine, and most of the available research is either funded by or conducted in direct collaboration with the licensor. There are a handful of small, acute studies examining subjective energy and focus outcomes in healthy adults; the designs are typically crossover, N is small, and independent replication is essentially absent. The “faster onset than theacrine” claim reads like a product differentiation pitch rather than a mechanistic finding that tells you anything actionable about the underlying pharmacology.

Here’s what we actually dont know: the full receptor binding profile. The adenosine antagonist claim is plausible given structural similarity to caffeine and theacrine, but specific affinity data for A1 and A2A subtypes is not clearly available in the open literature. That ambiguity might sound like a research opportunity. It isn’t. It’s more likely a sign that no serious academic group has prioritized the question in the seven-plus years since the ingredient was introduced to market. When industry-funded compounds fail to generate independent academic traction in that window, the absence is informative.

For probe value, caffeine remains the gold-standard adenosine antagonist for bench work, with decades of receptor binding data, knockout models, and well-characterized dose-response relationships behind it. If you’re doing A2A biology, you have better tools. If you’re interested in comparative pharmacokinetics within the purine alkaloid class, theacrine’s tolerance profile has at least generated some independent investigation; methylliberine’s PK data is thin. There’s no assay, no pathway, no model system where Dynamine opens a door that better-characterized compounds don’t already open more cleanly.

We don’t think this earns shelf space in a serious research library. It’s a trademarked supplement ingredient backed by a handful of company-sponsored trials and a plausible but uncharacterized mechanism. If the purine alkaloid space genuinely interests you, the research resources are better spent on theacrine’s habituation biology or the broader adenosine receptor field, where actual frontier work is happening.

Novelty: 32
Mechanism promise: 18
In-category differentiation: 20
Evidence quality: 18
Translational signal: 22
Research bench value: 18

Rationale Methylliberine’s proposed mechanism is adenosine antagonism, pharmacologically indistinguishable in kind from caffeine and theacrine, and the evidence base is almost entirely licensor-funded with no meaningful independent replication. The compound earns modest novelty points for being a relatively recent structural variant, but nothing in the available literature justifies prioritizing it over better-characterized tools in the same class.

Purine alkaloid (methylliberine)

A purine alkaloid related to theacrine, present in kucha tea, marketed as Dynamine for energy and focus applications.

Abstract

Dynamine (methylliberine; 9-methylliberine) is a purine alkaloid related to theacrine and present in kucha tea (Camellia kucha). The compound is marketed as Dynamine by Compound Solutions for energy and focus applications. Pharmacology likely overlaps with the broader methylxanthine class (adenosine antagonism) but specific receptor profile and clinical evidence base are limited. Doses are typically 50 to 200 mg per administration; Compound Solutions describes it as having faster onset than theacrine.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-166Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.